Bestaande gebruiker? Log in
Abonneren
Home
Beurs vandaag
Koersen
Nieuws
Agenda
Analisten
Analisten vandaag
Meest aanbevolen aandelen
Minst aanbevolen aandelen
Aandelen met grootste potentieel
Insider trading
Insiders vandaag
Meest gekochte aandelen
Meest verkochte aandelen
Mijn Trivano
Mijn Trivano
Mijn selecties
Mijn nieuwsbrieven
Abonneren
Beurs vandaag
Koersen
Nieuws
Agenda
Analisten
Insider trading
Mijn Trivano
Registreren / inloggen
Beurs vandaag
Amerika
PAVmed Inc
Nieuws
PAVmed Inc
PAVM
NAS
: PAVM
| ISIN: US70387R1068
9/05/2024
2,250 USD
(+2,27%)
(+2,27%)
9/05/2024
Aandeel volgen
Aandeel gevolgd
Samenvatting
Nieuws
Insiders
Technische analyse
TA
Toon enkel gratis nieuws
9 mei 2024 ·
Legacy Sponge-on-a-String Esophageal Cell Collection Device Subject of Class II FDA Recall
· Persbericht
7 mei 2024 ·
Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors
· Persbericht
3 mei 2024 ·
PAVmed to Hold a Business Update Conference Call and Webcast on May 14, 2024
· Persbericht
2 mei 2024 ·
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 13, 2024
· Persbericht
2 mei 2024 ·
Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing
· Persbericht
30 april 2024 ·
PAVmed Subsidiary, Veris Health, Signs Memorandum of Understanding with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
· Persbericht
29 april 2024 ·
Lucid Diagnostics Partners with the Esophageal Cancer Action Network (ECAN) to Highlight Esophageal Cancer Awareness Month
· Persbericht
8 april 2024 ·
Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
· Persbericht
27 maart 2024 ·
PAVmed Provides Business Update and Fourth Quarter and Full Year 2023 Financial Results
· Persbericht
21 maart 2024 ·
Lucid Diagnostics Announces Positive Data from the First Prospective Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population
· Persbericht
21 maart 2024 ·
PAVmed Launches Incubator to Advance Existing Pipeline Technologies including PortIO, EsoCure and CarpX
· Persbericht
20 maart 2024 ·
Lucid Diagnostics Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference
· Persbericht
13 maart 2024 ·
PAVmed to Hold a Business Update Conference Call and Webcast on March 27, 2024
· Persbericht
12 maart 2024 ·
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 26, 2024
· Persbericht
16 februari 2024 ·
Lucid Diagnostics Provides Update Regarding World Trade Center Health Program
· Persbericht
15 februari 2024 ·
Lucid Diagnostics Chairman & CEO, Dr. Lishan Aklog, Highlights EsoCheck® Esophageal Cell Collection Device during Congressional Testimony
· Persbericht
8 februari 2024 ·
Lucid Diagnostics Executes Contract to Provide EsoGuard® Esophageal Precancer Testing as a Covered Benefit for 9/11 Responders and Survivors
· Persbericht
12 december 2023 ·
Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Results from Three Clinical Utility Studies
· Persbericht
11 december 2023 ·
PAVmed Provides Additional Details for Upcoming Stock Dividend to Shareholders
· Persbericht
4 december 2023 ·
PAVmed Announces Dividend of Lucid Diagnostics Common Stock and Reverse Stock Split
· Persbericht
Aandeel volgen
Aandeel gevolgd
Mijn selecties
Voorbeeldselectie
Je selectie is nog leeg.
Voeg nu effecten toe